title: Up-regulation of circulating miR-20a is correlated with hepatitis C virus-mediated liver disease progression.
abstract: Chronic hepatitis C virus (HCV) infection is one of the major causes of liver fibrosis and liver transplantation in the United States. Circulating microRNAs (miRNAs) in the blood are emerging as biomarkers for pathological conditions. In the present study we performed a systematic screening approach to identify up-regulated miRNAs in the plasma/serum of HCV-infected patients with different stages of hepatic histological disease severity. We initially screened serum samples of HCV-infected patients with fibrosis and compared them with sera of healthy volunteers using serum miRNA array profiling and identified a group of modulated miRNAs. Subsequent study demonstrated that miR-20a and miR-92a in HCV-infected fibrosis patients sera were significantly up-regulated when compared with that of healthy volunteers or non-HCV-associated liver disease. We have also observed an increase of plasma miR-20a and miR-92a in acute and chronic HCV-infected patients as compared to that of healthy volunteers. However, there was no correlation between the plasma/serum levels of any of these miRNAs with HCV viral loads. We next investigated longitudinal plasma samples from HCV-infected patients. Our results suggested that miR-20a and miR-92a remained unaltered in HCV-infected patients who progressed from acute to chronic infection. On the other hand, miR-92a expression was reduced in acute to resolved individuals. These data provide evidence that plasma/serum levels of miR-20a and miR-92a have potential as sensitive and cost-effective biomarkers for early detection of HCV infection.
  
  
  CONCLUSIONS
  Circulating miR-20a may serve as a potential for predictive biomarker in HCV-mediated fibrosis.
authors: Department of Pathology, Saint Louis University, St. Louis, MO, USA.
authors: Shubham
authors: S
authors: Shrivastava
authors: Jessica
authors: J
authors: Petrone
authors: Robert
authors: R
authors: Steele
authors: Georg M
authors: GM
authors: Lauer
authors: Adrian M
authors: AM
authors: Di Bisceglie
authors: Ratna B
authors: RB
authors: Ray
mesh_terms: D000328:Adult; D000368:Aged; D015415:Biomarkers / Q000097:blood; D016022:Case-Control Studies; D004279:DNA, Viral / Q000097:blood; D018450:Disease Progression; D005260:Female; D016174:Hepacivirus / Q000235:genetics; D006526:Hepatitis C / Q000097:blood*; D006801:Humans; D008103:Liver Cirrhosis / Q000097:blood* / Q000821:virology*; D008297:Male; D035683:MicroRNAs / Q000097:blood*; D008875:Middle Aged; D011237:Predictive Value of Tests; D012720:Severity of Illness Index; D015854:Up-Regulation / Q000502:physiology*; D019562:Viral Load
chemical_list: D015415:Biomarkers; D004279:DNA, Viral; C534451:MIRN20a microRNA, human; C541874:MIRN92 microRNA, human; D035683:MicroRNAs
references: Proc Natl Acad Sci U S A. 2011 Apr 19;108(16):6573-8
references: 21460253
references: PLoS One. 2008 Sep 05;3(9):e3148
references: 18773077
references: J Virol. 2006 May;80(9):4633-9
references: 16611923
references: Cancer Cell. 2008 Mar;13(3):272-86
references: 18328430
references: Int J Cancer. 2011 Feb 1;128(3):608-16
references: 20473869
references: Hepatology. 2011 Nov;54(5):1767-76
references: 22045675
references: PLoS One. 2012;7(7):e41561
references: 22859996
references: Mol Cancer. 2010 Nov 26;9:306
references: 21110877
references: J Clin Oncol. 2010 Apr 1;28(10):1721-6
references: 20194856
references: Cancer Res. 2010 Dec 1;70(23):9798-807
references: 21098710
references: Ann Intern Med. 2000 Feb 15;132(4):296-305
references: 10681285
references: J Clin Oncol. 2011 Dec 20;29(36):4781-8
references: 22105822
references: J Hepatol. 2013 Feb;58(2):234-9
references: 23085648
references: PLoS One. 2011;6(8):e23937
references: 21886843
references: Int J Cancer. 2010 Jul 1;127(1):118-26
references: 19876917
references: Gynecol Oncol. 2009 Jan;112(1):55-9
references: 18954897
references: Gastroenterology. 2008 May;134(6):1699-714
references: 18471548
references: PLoS One. 2009;4(5):e5532
references: 19440243
references: Proc Natl Acad Sci U S A. 2009 Mar 17;106(11):4402-7
references: 19246379
references: Ann Intern Med. 1996 Oct 15;125(8):634-9
references: 8849147
references: J Cancer. 2012;3:432-48
references: 23074383
references: J Clin Invest. 2011 Aug;121(8):3343-56
references: 21747166
references: Hepatology. 2012 Nov;56(5):1946-57
references: 22684891
references: J Viral Hepat. 2011 Nov;18(11):745-59
references: 21992794
references: Nat Rev Genet. 2008 Feb;9(2):102-14
references: 18197166
references: Am J Gastroenterol. 2011 Sep;106(9):1663-9
references: 21606975
references: Hepatology. 2012 May;55(5):1640-2; author reply 1642-3
references: 22213067
references: Cell Res. 2008 Oct;18(10):997-1006
references: 18766170
references: Mol Carcinog. 2011 Feb;50(2):136-42
references: 21229610
references: Genes Dev. 2010 Jan 1;24(1):1-4
references: 20047995
references: RNA. 2003 Mar;9(3):277-9
references: 12592000
references: RNA. 2008 May;14(5):844-52
references: 18375788
references: Proc Natl Acad Sci U S A. 2008 Jul 29;105(30):10513-8
references: 18663219
references: Lab Invest. 2010 Dec;90(12):1727-36
references: 20625373
references: Mol Med Rep. 2012 Jun;5(6):1428-32
references: 22427142
references: Clin Cancer Res. 2008 May 1;14(9):2588-92
references: 18451220
references: PLoS One. 2011;6(10):e26971
references: 22066022